In this randomized , open-label , multicenter phase III study , patients were randomly assigned to receive SOX ( @-@ mg/day S-@ for @ weeks with @ mg/m ( @ ) oxaliplatin on day @ , every @ weeks ) or CS ( S-@ for @ weeks with @ mg/m ( @ ) cisplatin on day @ , every @ weeks ) .